Literature DB >> 29482028

The Current Focus of Heart Failure Clinical Trials.

Naga Venkata Pothineni1, Ajoe John Kattoor1, Swathi Kovelamudi1, Satish Kenchaiah2.   

Abstract

BACKGROUND: Heart failure (HF) is a major global health problem. Clinical trials test efficacy, effectiveness, and safety of novel and emerging therapies in HF. We sought to determine the salient features of ongoing interventional clinical trials in HF. METHODS AND
RESULTS: We accessed the ClinicalTrials.gov registry of the National Institutes of Health (NIH) and the International Clinical Trials Registry Platform of the World Health Organization on January 1, 2017, and extracted pertinent information on current HF clinical trials for systematic review. Of 794 HF trials that met our inclusion criteria, almost one-half (49.1%) evaluated clinical end points and one-third (32.8%) examined imaging end points as primary outcomes. One-fourth (24.8%) were industry sponsored and one-third (35.6%) were university sponsored. The NIH and other United States federal agencies funded only 14 trials (1.8% of all trials; 10.7% of trials in the US). Among 536 HF trials with specified left ventricular ejection fraction status, 434 (81.0%) focused on HF with reduced ejection fraction (HFrEF) and only 102 (19.0%) trials targeted HF with preserved ejection fraction (HFpEF).
CONCLUSIONS: Ongoing HF trials are predominantly sponsored by nongovernmental funding agencies. Although HFpEF occurs as commonly as HFrEF in the community, the number of clinical trials targeting HFpEF is substantially lower compared with HFrEF. Published by Elsevier Inc.

Entities:  

Keywords:  Clinical trials; heart failure

Mesh:

Year:  2018        PMID: 29482028      PMCID: PMC6800082          DOI: 10.1016/j.cardfail.2018.02.006

Source DB:  PubMed          Journal:  J Card Fail        ISSN: 1071-9164            Impact factor:   5.712


  38 in total

1.  2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines.

Authors:  Clyde W Yancy; Mariell Jessup; Biykem Bozkurt; Javed Butler; Donald E Casey; Mark H Drazner; Gregg C Fonarow; Stephen A Geraci; Tamara Horwich; James L Januzzi; Maryl R Johnson; Edward K Kasper; Wayne C Levy; Frederick A Masoudi; Patrick E McBride; John J V McMurray; Judith E Mitchell; Pamela N Peterson; Barbara Riegel; Flora Sam; Lynne W Stevenson; W H Wilson Tang; Emily J Tsai; Bruce L Wilkoff
Journal:  Circulation       Date:  2013-06-05       Impact factor: 29.690

2.  A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure.

Authors:  J N Cohn; G Johnson; S Ziesche; F Cobb; G Francis; F Tristani; R Smith; W B Dunkman; H Loeb; M Wong
Journal:  N Engl J Med       Date:  1991-08-01       Impact factor: 91.245

Review 3.  The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis.

Authors: 
Journal:  Eur Heart J       Date:  2011-08-06       Impact factor: 29.983

4.  Spironolactone for heart failure with preserved ejection fraction.

Authors:  Bertram Pitt; Marc A Pfeffer; Susan F Assmann; Robin Boineau; Inder S Anand; Brian Claggett; Nadine Clausell; Akshay S Desai; Rafael Diaz; Jerome L Fleg; Ivan Gordeev; Brian Harty; John F Heitner; Christopher T Kenwood; Eldrin F Lewis; Eileen O'Meara; Jeffrey L Probstfield; Tamaz Shaburishvili; Sanjiv J Shah; Scott D Solomon; Nancy K Sweitzer; Song Yang; Sonja M McKinlay
Journal:  N Engl J Med       Date:  2014-04-10       Impact factor: 91.245

5.  Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.

Authors:  Bertram Pitt; Willem Remme; Faiez Zannad; James Neaton; Felipe Martinez; Barbara Roniker; Richard Bittman; Steve Hurley; Jay Kleiman; Marjorie Gatlin
Journal:  N Engl J Med       Date:  2003-03-31       Impact factor: 91.245

6.  Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database.

Authors:  Clyde W Yancy; Margarita Lopatin; Lynne Warner Stevenson; Teresa De Marco; Gregg C Fonarow
Journal:  J Am Coll Cardiol       Date:  2005-12-15       Impact factor: 24.094

7.  Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators.

Authors:  M A Pfeffer; E Braunwald; L A Moyé; L Basta; E J Brown; T E Cuddy; B R Davis; E M Geltman; S Goldman; G C Flaker
Journal:  N Engl J Med       Date:  1992-09-03       Impact factor: 91.245

8.  Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial.

Authors:  Margaret M Redfield; Horng H Chen; Barry A Borlaug; Marc J Semigran; Kerry L Lee; Gregory Lewis; Martin M LeWinter; Jean L Rouleau; David A Bull; Douglas L Mann; Anita Deswal; Lynne W Stevenson; Michael M Givertz; Elizabeth O Ofili; Christopher M O'Connor; G Michael Felker; Steven R Goldsmith; Bradley A Bart; Steven E McNulty; Jenny C Ibarra; Grace Lin; Jae K Oh; Manesh R Patel; Raymond J Kim; Russell P Tracy; Eric J Velazquez; Kevin J Anstrom; Adrian F Hernandez; Alice M Mascette; Eugene Braunwald
Journal:  JAMA       Date:  2013-03-27       Impact factor: 56.272

Review 9.  Developing therapies for heart failure with preserved ejection fraction: current state and future directions.

Authors:  Javed Butler; Gregg C Fonarow; Michael R Zile; Carolyn S Lam; Lothar Roessig; Erik B Schelbert; Sanjiv J Shah; Ali Ahmed; Robert O Bonow; John G F Cleland; Robert J Cody; Ovidiu Chioncel; Sean P Collins; Preston Dunnmon; Gerasimos Filippatos; Martin P Lefkowitz; Catherine N Marti; John J McMurray; Frank Misselwitz; Savina Nodari; Christopher O'Connor; Marc A Pfeffer; Burkert Pieske; Bertram Pitt; Giuseppe Rosano; Hani N Sabbah; Michele Senni; Scott D Solomon; Norman Stockbridge; John R Teerlink; Vasiliki V Georgiopoulou; Mihai Gheorghiade
Journal:  JACC Heart Fail       Date:  2014-04       Impact factor: 12.035

10.  Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction.

Authors:  Margaret M Redfield; Kevin J Anstrom; James A Levine; Gabe A Koepp; Barry A Borlaug; Horng H Chen; Martin M LeWinter; Susan M Joseph; Sanjiv J Shah; Marc J Semigran; G Michael Felker; Robert T Cole; Gordon R Reeves; Ryan J Tedford; W H Wilson Tang; Steven E McNulty; Eric J Velazquez; Monica R Shah; Eugene Braunwald
Journal:  N Engl J Med       Date:  2015-11-08       Impact factor: 91.245

View more
  1 in total

Review 1.  Beyond the myocardium? SGLT2 inhibitors target peripheral components of reduced oxygen flux in the diabetic patient with heart failure with preserved ejection fraction.

Authors:  Mouhamed Nashawi; Omar Sheikh; Ayman Battisha; Mahnoor Mir; Robert Chilton
Journal:  Heart Fail Rev       Date:  2022-01       Impact factor: 4.214

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.